NEPHROGENEX, INC. (NRXGQ) financial statements (2021 and earlier)

Company profile

Business Address 3200 BEECHLEAF COURT
RALEIGH, NC 27604
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments22211924292730
Cash and cash equivalents1919101614812
Short-term investments3298151918
Restricted cash and investments00     
Deferred costs  0    
Other undisclosed current assets1111000
Total current assets:23222025292730
Noncurrent Assets
Property, plant and equipment0000000
Other noncurrent assets0000000
Other undisclosed noncurrent assets  0    
Total noncurrent assets:0010000
TOTAL ASSETS:23222125292731
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3332322
Accounts payable2222211
Accrued liabilities0010000
Employee-related liabilities1110110
Debt2   0  
Other undisclosed current liabilities2343011
Total current liabilities:8675332
Noncurrent Liabilities
Long-term debt and lease obligation45566  
Long-term debt, excluding current maturities45566  
Liabilities, other than long-term debt00000  
Other liabilities00000  
Total noncurrent liabilities:45566  
Total liabilities:121112111032
Stockholders' equity
Stockholders' equity attributable to parent1111814192428
Common stock0000000
Additional paid in capital92867877777777
Accumulated other comprehensive loss(0)(0)(0)(0)(0)(0)(0)
Accumulated deficit(81)(75)(69)(63)(58)(53)(48)
Total stockholders' equity:1111814192428
TOTAL LIABILITIES AND EQUITY:23222125292731

Income statement (P&L) ($ in millions)

12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
Operating expenses(6)(5)(6)(5)(5)(4)(5)
Operating loss:(6)(5)(6)(5)(5)(4)(5)
Nonoperating income
(Investment Income, Nonoperating)
0000000
Interest and debt expense(0)(0)(0)(0)(0)  
Net loss available to common stockholders, diluted:(6)(5)(6)(5)(5)(4)(5)

Comprehensive Income ($ in millions)

12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
12/31/2014
Q4
9/30/2014
Q3
6/30/2014
Q2
Net loss:(6)(5)(6)(5)(5)(4)(5)
Comprehensive loss:(6)(5)(6)(5)(5)(4)(5)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0(0)000(0)
Comprehensive loss, net of tax, attributable to parent:(6)(5)(6)(5)(5)(4)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: